Javlor (Vinflunine)

Javlor (vinflunine) is a chemotherapy medicine used on its own for adults with advanced or metastatic transitional cell cancer of the urinary tract (including the bladder) after a platinum-containing regimen has failed. It is given as a 20-minute intravenous infusion every 3 weeks.

Vinflunine binds to tubulin, the protein cells use to build the structure they need to divide, which stops cancer cells from dividing. In the main study, 253 patients received vinflunine with best supportive care and 117 received best supportive care alone. Median survival was 6.9 versus 4.6 months; the difference was statistically significant after adjusting for prognostic factors.

• Low white blood cell counts (neutropenia), anaemia and tiredness are very common. Treatment must not start if neutrophils are below 1,500/mm³ or platelets below 100,000/mm³, and blood counts are checked before each cycle.
• Constipation is common and can be serious. Laxatives and diet measures are recommended from day 1 to day 5–7 of each cycle.
• QT prolongation, low sodium and posterior reversible encephalopathy syndrome have been reported.
• Not to be used while breastfeeding. It has not been studied in patients with a performance status of 2 or more.

Is Javlor still available?

Its EU authorisation is still valid. It is no longer marketed in France (from June 2026), but Italy and Spain still supply it. We confirm the country of supply and stock before quoting.

Which vials should be ordered?

The dose is calculated from body surface area: usually 320 mg/m², or 280 mg/m² for some patients, with further reductions for kidney or liver problems and for patients aged 75 and over. The oncologist should give the dose in mg and the number of cycles, and we will match it to the vial sizes that are available (2 mL and 10 mL vials are the ones currently marketed in Italy).

What documents do we need?

• A prescription from the medical oncologist with the dose in mg and the number of cycles
• A histopathology report and a summary of previous platinum chemotherapy
• Government-issued photo ID of the patient

We confirm the order only after the prescription has been checked.

How is Javlor stored and shipped?

Unopened vials must be kept in a refrigerator at 2–8 °C, in the original box to protect them from light, so it is shipped in a cold chain. It is a cytotoxic medicine and should be prepared in a hospital chemotherapy unit.

Javlor needs cold-chain shipping and goes straight to the treating hospital’s pharmacy. IPN sources it through authorised distributors in markets where it is still sold and arranges the named-patient import.

For Javlor price in India and delivery time, call +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• European Union: Authorised on 21 September 2009 (Pierre Fabre). Marketing in France stopped on 30 June 2026, but it is still marketed in Italy and Spain.
• United States: Not approved.

Sources:

• Javlor – EMA EPAR (authorisation status)
• Javlor – EU product information (SmPC)
• Javlor – French public medicines database (marketing stopped 30/06/2026)

Information last checked: October 2026.

Why is Javlor prescribed?

Doctors prescribe Javlor for advanced or metastatic urothelial (bladder) cancer after platinum chemotherapy. It is a vinca alkaloid chemotherapy.

Who is the maker of Javlor?

It is made by Pierre Fabre Médicament (France).

How does Vinflunine act in the body?

Vinflunine binds to tubulin, the protein cells use to build the structure they need to divide, which stops cancer cells from dividing.

How often is Javlor given?

It is given as a 20-minute intravenous infusion once every 3 weeks.

Why is the Javlor dose sometimes lower than 320 mg/m²?

The label starts some patients at 280 mg/m² (for example, performance status 1 or previous pelvic radiotherapy) and lowers the dose for kidney or liver problems, for age 75 and over, and after serious side effects.

Is Javlor FDA approved?

No. Javlor is not approved by the US FDA.